Matteo Righi

This inventor holds 11 USPTO granted patents and 6 published patent applications and 2 EPO patents. Top assignee: Autolus Limited. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matteo Righi. Retrieved from https://idiyas.com/inventor/matteo-righi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 6)

% Patents Active = 90.9

EPO Patents = 2 (Patent Applications = 11)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 13(Granted Patents)

Company Filing History:

11 out of 58

Autolus Limited

patents

Years Active: 2020-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624088 - CHIMERIC RECEPTOR COMPRISING A LIGAND BINDING DOMAIN AND AN ENDODOMAIN COMPRISING A CYTOKINE RECEPTOR ENDODOMAIN AND AN INTRACELLULAR T CELL SIGNALLING DOMAIN (2026-05-12),

2. 12234295 - Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof (2025-02-25),

3. 12187769 - Cell (2025-01-07),

4. 11701386 - Cell (2023-07-18),

5. 11648274 - Polypeptide (2023-05-16),

6. 11479614 - Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors (2022-10-25),

7. 11479613 - Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins (2022-10-25),

8. 11365262 - Cell (2022-06-21),

9. 11242377 - Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomains (2022-02-08),

10. 10800855 - Chimeric cytokine receptors and encoding nucleic acids (2020-10-13),

11. 10800854 - Chimeric cytokine receptors and encoding nucleic acids (2020-10-13),

Title: The Innovative Contributions of Matteo Righi

Introduction

Matteo Righi is a prominent inventor based in London, GB, known for his significant contributions to the field of biotechnology. With a total of 10 patents to his name, Righi has made remarkable advancements in the development of chimeric proteins and cell-based therapies. His work has the potential to revolutionize treatments for various diseases.

Latest Patents

One of Righi's latest patents is focused on a chimeric transmembrane protein that comprises antibody dimerization domains and a type I cytokine receptor endodomain. This invention provides a chimeric cytokine receptor (CCR) that includes an exodomain capable of binding to ligands such as tumor-secreted factors, chemokines, and cell-surface antigens. Additionally, he has developed a patent related to a cell that incorporates a chimeric antigen receptor (CAR) along with a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

Career Highlights

Righi's career is marked by his innovative research and development efforts at Autolus Limited, a company dedicated to advancing cell and gene therapies. His expertise in creating novel therapeutic solutions has positioned him as a key figure in the biotechnology sector.

Collaborations

Throughout his career, Righi has collaborated with notable colleagues, including Martin Pulé and Shaun Cordoba. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in their field.

Conclusion

Matteo Righi's contributions to biotechnology through his patents and collaborative efforts highlight his role as an influential inventor. His work continues to pave the way for innovative therapies that could significantly impact patient care in the future.

Profile summary based on public USPTO records.